CD44 and acute myeloid leukemia: Anti-CD44 antibodies have been trialed in pre-clinical and clinical studies, and were shown to eradicate AML stem cells in mouse models (Jin et al., 2006), although their clinical activity so far is very limited (Vey et al., 2016).